Copyright © 2004, European Society of Cardiology
Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart–gene therapy
aDepartment of Biotechnology and Molecular Medicine, A. I. Virtanen Institute, Kuopio, Finland
bDepartment of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
cGene Therapy Unit, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
* Corresponding author. Department of Biotechnology and Molecular Medicine, A. I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. Tel.: +358 17 162075; fax: +358 17 163751. Email address: Seppo.Ylaherttuala{at}uku.fi
Myocardial ischemia is one of the most promising targets of gene therapy. Although several growth factors and delivery approaches have yielded positive results in preclinical studies, first clinical studies have shown little or no real clinical benefit to the patients. It is likely that less than optimal gene therapy approaches have been used so far, and more thorough preclinical studies are needed in order to establish safe, efficient pro-angiogenic therapy. Growth factor, gene transfer vector, delivery method and target microenvironment need to be chosen based on the therapeutic target. It has become apparent that induction of large collateral arteries in the myocardium may need a different approach than rapid growth of neovasculature around infarction scar. Large animal models are necessary in the determination of optimal therapeutic agent, dose and clinically relevant delivery strategy.
KEYWORDS Angiogenesis; Collateral arteries; Capillaries; Gene delivery; VEGF
Time for primary review 34 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Alfranca VEGF therapy: a timely retreat Cardiovasc Res, September 1, 2009; 83(4): 611 - 612. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Chambers Editorial comment Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 651 - 652. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okazaki, S. Ebihara, M. Asada, S. Yamanda, Y. Saijo, Y. Shiraishi, T. Ebihara, K. Niu, H. Mei, H. Arai, et al. Macrophage Colony-Stimulating Factor Improves Cardiac Function after Ischemic Injury by Inducing Vascular Endothelial Growth Factor Production and Survival of Cardiomyocytes Am. J. Pathol., October 1, 2007; 171(4): 1093 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ye, H. K. Haider, S. Jiang, R. S. Tan, W. C. Toh, R. Ge, and E. K.W. Sim Angiopoietin-1 for myocardial angiogenesis: A comparison between delivery strategies Eur J Heart Fail, May 1, 2007; 9(5): 458 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Muller, H. A. Katus, and R. Bekeredjian Targeting the heart with gene therapy-optimized gene delivery methods Cardiovasc Res, February 1, 2007; 73(3): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Germani, F. Limana, and M. C. Capogrossi Pivotal Advances: High-mobility group box 1 protein--a cytokine with a role in cardiac repair J. Leukoc. Biol., January 1, 2007; 81(1): 41 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferrarini, N. Arsic, F. A. Recchia, L. Zentilin, S. Zacchigna, X. Xu, A. Linke, M. Giacca, and T. H. Hintze Adeno-Associated Virus-Mediated Transduction of VEGF165 Improves Cardiac Tissue Viability and Functional Recovery After Permanent Coronary Occlusion in Conscious Dogs Circ. Res., April 14, 2006; 98(7): 954 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Godecke AAV vector re-targeting: A small step on the way to cardiac-specific gene transfer Cardiovasc Res, April 1, 2006; 70(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
|
|
M. Post and J. Waltenberger Modulation of growth factor action in the cardiovascular system Cardiovasc Res, February 15, 2005; 65(3): 547 - 549. [Full Text] [PDF]
|
|